News Agencies Feed

healthcare

Sep 24

Vifor Pharma announces outcome of AFFIRM-AHF topline data

Vifor Pharma announces outcome of AFFIRM-AHF topline data

  • The study narrowly missed statistical significance on the primary endpoint
  • Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage
  • The totality of evidence suggests that Ferinject® is clinically beneficial in high risk heart failure patients

Regulatory"...

Continue Reading >>

Sep 22

Hassan Recommends Two-Week Total Lockdown as Virus Cases Hit 1,006

Hassan Recommends Two-Week Total Lockdown as Virus Cases Hit 1,006

Health Minister Hamad Hassan recommended a total two-week lockdown to stem the alarming rise in daily detected coronavirus infections, but authorities say it finds it difficult to impose another lockdown amid an unprecedented economic collapse.

Lebanon"...

Continue Reading >>

Sep 22

Lebanon on verge of crisis as medicines in short supply

Lebanon on verge of crisis as medicines in short supply

Lebanon is facing a new crisis, as medicines are in short supply and supplies are taking more than four weeks to secure.

Beirut based pharmacist, Mahdi, told Asharq Al-Awsat news site that the crisis is partly"...

Continue Reading >>

Sep 20

Saudi aid agency opens dialysis center in Beirut

Saudi aid agency opens dialysis center in Beirut

The King Salman Humanitarian Aid and Relief Center (KSRelief) inaugurated the final stage of equipping the dialysis center at Al-Makassed Hospital in Beirut, in the presence of Saudi Ambassador to Lebanon Walid bin Abdullah Bukhari.
The executive director of Al-Makassed Hospital,"...

Continue Reading >>

Sep 20

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial......

Continue Reading >>

Sep 20

Over 200 detainees infected with coronavirus in Lebanon prison

Over 200 detainees infected with coronavirus in Lebanon prison

Some 200 detainees in Beirut’s Roumieh prison have contracted the coronavirus, the Lebanese Order of Physicians announced.

President of the Lebanese Order of Physicians, Charaf Abou Charaf, said at a press"...

Continue Reading >>

Sep 18

Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in Secondary Immunodeficiency in Chronic Lymphocytic Leukaemia) study was initiated in Milan, Italy, and patient recruitment is underway. Additional sites"...

Continue Reading >>

Sep 18

Vifor Pharma Group Announces Successful Sale of OM Pharma

Vifor Pharma Group Announces Successful Sale of OM Pharma

  • Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435
  • In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500
  • Closure of the transaction is expected within...

    Continue Reading >>

Sep 17

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

  • First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients
  • Study is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition

Boehringer"...

Continue Reading >>

Sep 16

Sir Richard Branson Joins Dr. Anthony Fauci and Dr. Sanjay Gupta as Keynote Speakers for Everbridge’s Virtual Symposium, COVID-19: Road to Recovery (R2R), October 14-15, 2020

Sir Richard Branson Joins Dr. Anthony Fauci and Dr. Sanjay Gupta as Keynote Speakers for Everbridge’s Virtual Symposium, COVID-19: Road to Recovery (R2R), October 14-15, 2020

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the addition of premier keynotes and other business, healthcare and government executive speakers for its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid the COVID-19 pandemic. Virgin Group Founder Sir Richard Branson joins presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci and renowned neurosurgeon and CNN Chief Medical Correspondent......

Continue Reading >>